The Hypothalamic-Pituitary-Thyroid axis is the neuroendocrine feedback system that governs thyroid hormone production and, through it, the basal metabolic rate of virtually every cell in the body. The Hypothalamus releases thyrotropin-releasing hormone (TRH), which stimulates the anterior pituitary gland to secrete thyroid-stimulating hormone (TSH, thyrotropin), which in turn drives the thyroid gland to synthesise and release the prohormone thyroxine (T4) and, to a lesser extent, the biologically active triiodothyronine (T3). Because T3 acts on nuclear receptors that directly regulate gene transcription in nearly every tissue, the HPT axis is the body's master thermostat for metabolism, thermoregulation, oxygen consumption, protein synthesis, and mitochondrial biogenesis. In cPNI it occupies a position of equal importance to the HPA axis: where the HPA axis orchestrates the acute and chronic stress response, the HPT axis sets the background metabolic tempo against which all other physiological programmes operate.
From an evolutionary perspective, the HPT axis represents one of the oldest vertebrate endocrine systems, conserved across fish, amphibians, reptiles, birds, and mammals. Its ancestral role was to couple environmental energy availability and temperature to reproductive timing, growth, and metamorphosis. In humans, this ancient function persists: fasting, cold exposure, inflammation, and chronic stress all modulate the HPT axis to redistribute energy in ways that made sense on the savannah but become pathological in the modern mismatch environment. The ability of inflammatory cytokines to suppress HPT output -- the so-called non-thyroidal illness syndrome -- is not a defect but an evolutionary energy-conservation strategy that diverts calories away from growth and cognition toward immune activation. Understanding this evolutionary logic is central to cPNI clinical reasoning and prevents the reflexive impulse to "correct" every low T3 with levothyroxine.
The HPT axis does not operate in isolation. It is intimately coupled to the HPA axis (cortisol suppresses TSH and inhibits peripheral T4-to-T3 conversion), the HPG Axis (thyroid hormones modulate sex hormone-binding globulin and gonadal sensitivity to gonadotropins), the HPS-axis (growth hormone and IGF-1 interact with thyroid status for linear growth and anabolism), and Leptin signalling (leptin from adipose tissue stimulates TRH neurons, linking energy stores to metabolic rate). This web of cross-talk means that isolated assessment of TSH, while convenient, frequently misleads the clinician who does not consider the full neuroendocrine and inflammatory context.
The cascade begins in the Hypothalamus, specifically in the hypophysiotropic TRH neurons of the paraventricular nucleus (PVN). These neurons integrate inputs from multiple sources: Leptin from adipose tissue provides a tonic stimulatory signal proportional to fat mass, alpha-melanocyte-stimulating hormone (alpha-MSH) from the Nucleus Arcuatus relays nutritional status, Cortisol from the HPA axis exerts an inhibitory tone, and pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β suppress TRH transcription via NF-κB-mediated pathways. The PVN TRH neurons also receive photoperiod information via the suprachiasmatic nucleus, coupling the HPT axis to circadian and seasonal rhythms -- a mechanism that explains the well-documented seasonal variation in TSH levels, with higher values in winter and lower in summer.
TRH is a tripeptide (pyroglutamyl-histidyl-prolineamide) released into the hypophyseal portal vasculature, where it travels the short distance to the anterior pituitary gland and binds TRH receptors (TRH-R1) on thyrotrope cells. This triggers a Gq-protein/phospholipase C/inositol triphosphate (IP3) cascade that mobilises intracellular calcium and activates protein kinase C, resulting in rapid exocytosis of preformed TSH and, over hours, upregulation of TSH beta-subunit gene transcription. TSH is a heterodimeric glycoprotein sharing its alpha subunit with LH, FSH, and hCG -- a fact with clinical relevance in Pregnancy, where high hCG in the first trimester cross-activates the TSH receptor and physiologically suppresses TSH.
TSH enters the systemic circulation and binds the TSH receptor (TSHR), a G-protein-coupled receptor on thyroid follicular cells. TSHR activation stimulates every step of thyroid hormone biosynthesis: uptake of Iodine (as iodide) from the blood via the sodium-iodide symporter (NIS), oxidation of iodide to iodine by thyroid peroxidase (TPO) using hydrogen peroxide generated by the DUOX2 enzyme, incorporation of iodine into Tyrosine residues on thyroglobulin (forming monoiodotyrosine, MIT, and diiodotyrosine, DIT), coupling of two DIT residues to form T4 or one DIT with one MIT to form T3, endocytosis and proteolysis of iodinated thyroglobulin to liberate T4 and T3 into the bloodstream, and growth and vascularisation of the thyroid gland itself. The thyroid produces approximately 80-100 micrograms of T4 daily and only about 5-10 micrograms of T3. The remaining T3 required by the body -- roughly 25-30 micrograms per day -- must be generated by peripheral conversion.
The conversion of T4 to T3 in peripheral tissues is catalysed by the iodothyronine deiodinase family, a group of Selenium-dependent selenoenzymes that are among the most important regulatory nodes in the entire HPT axis. Type 1 deiodinase (D1), expressed primarily in the Liver, kidneys, and thyroid, removes an iodine from the outer ring of T4 to produce T3 and contributes to the circulating T3 pool; it is upregulated by T3 itself and by TSH, and downregulated by inflammation. Type 2 deiodinase (D2), expressed in the brain, pituitary, brown adipose tissue, skeletal muscle, and placenta, generates T3 locally for intracellular use; it is critically important because it maintains brain T3 levels even when circulating T3 falls, and it is the enzyme responsible for the thermogenic response in brown adipose tissue during cold exposure. D2 is upregulated by cold, by sympathetic stimulation via beta-adrenergic receptors, and by TSH, and is degraded by ubiquitination when T4 levels are high -- a rapid autoregulatory mechanism. Type 3 deiodinase (D3) is the inactivating enzyme: it removes an iodine from the inner ring of T4 to produce reverse T3 (rT3), which is biologically inactive at thyroid receptors, and it also converts T3 to T2, further reducing active hormone levels. D3 is powerfully upregulated by inflammatory cytokines (especially IL-6 and TNF-α), by Cortisol, and by hypoxia. The balance between D2 (activating) and D3 (inactivating) at the tissue level determines the local T3 concentration and therefore the metabolic state of each organ -- a concept sometimes called intracellular hypothyroidism, which can exist even when serum TSH and T4 are normal.
Thyroid hormones exert their classical genomic effects by binding to thyroid hormone receptors (TR-alpha and TR-beta), which are members of the nuclear receptor superfamily. TR-alpha predominates in the heart, brain, skeletal muscle, and bone; TR-beta predominates in the Liver, pituitary, and inner ear. Unliganded TRs sit on thyroid response elements (TREs) in gene promoters complexed with corepressors (NCoR, SMRT), actively silencing transcription. When T3 binds, a conformational change releases corepressors and recruits coactivators, switching on transcription of target genes involved in mitochondrial biogenesis (PGC-1alpha), oxidative phosphorylation (cytochrome c oxidase, ATP synthase subunits), uncoupling protein expression (UCP1 in brown fat, UCP3 in muscle), lipid metabolism (LDL receptor upregulation, cholesterol-7alpha-hydroxylase), glucose metabolism (GLUT4 translocation), and protein synthesis. T3 also has rapid non-genomic effects mediated by integrin alphavbeta3 at the cell membrane, activating PI3K/Akt and MAPK/ERK pathways to stimulate angiogenesis, cell proliferation, and sodium-potassium ATPase activity. These non-genomic actions are important in the cardiovascular system, where T3 acutely increases heart rate, cardiac output, and peripheral vasodilation.
The negative feedback loop operates at two principal levels. T3 (largely generated locally by D2 in the pituitary and hypothalamus) suppresses TSH gene transcription in thyrotropes by binding TR-beta2, and it suppresses TRH gene transcription in the PVN. T4 also feeds back, but primarily after local conversion to T3 by D2. This means that the pituitary's "reading" of thyroid status depends critically on D2 activity within the pituitary itself -- an important subtlety, because conditions that alter peripheral D2 or D3 activity (such as inflammation) can create a dissociation between what the pituitary "sees" and what the tissues experience. The result is a normal TSH with low tissue T3 -- the hallmark of non-thyroidal illness syndrome and a frequent trap for clinicians who rely solely on TSH.
In cPNI practice, HPT axis dysfunction is among the most common and most frequently mismanaged clinical presentations. The standard biomedical approach of measuring TSH alone and treating only overt hypothyroidism misses the vast middle ground of subclinical thyroid dysfunction, tissue-level hypothyroidism, and inflammation-driven HPT suppression that accounts for an enormous burden of fatigue, cognitive decline, Depression, weight gain, cold intolerance, constipation, dry skin, hair loss, and elevated LDL cholesterol. The cPNI practitioner must understand that a "normal" TSH does not exclude clinically significant thyroid insufficiency, particularly in the context of chronic inflammation, chronic stress, obesity, or insulin resistance. A full thyroid panel -- TSH, free T4, free T3, reverse T3, anti-TPO antibodies, anti-thyroglobulin antibodies -- combined with clinical assessment of symptoms, body temperature, and metabolic markers, is the minimum standard. The ratio of free T3 to reverse T3 is particularly informative: a low ratio suggests excessive D3 activity and points toward an inflammatory or stress-driven aetiology rather than primary thyroid disease.
Non-thyroidal illness syndrome (NTIS), also called euthyroid sick syndrome or low-T3 syndrome, is perhaps the most important HPT-axis concept in cPNI. During acute or chronic illness, inflammatory cytokines (IL-6, TNF-α, IL-1β, IFN-γ) suppress every level of the axis: they reduce hypothalamic TRH, reduce pituitary TSH secretion, impair NIS-mediated iodide uptake in the thyroid, shift peripheral deiodination from the activating D1/D2 pathway toward the inactivating D3 pathway, and increase reverse T3 production. The result is low T3, elevated rT3, and paradoxically normal or even low TSH -- a pattern that standard thyroid testing may report as "euthyroid." From an evolutionary standpoint, this is an adaptive energy-conservation programme: during infection or injury, the body deliberately lowers its metabolic rate to redirect glucose and amino acids toward the immune system and wound healing. The clinical problem arises when this programme remains chronically activated by low-grade inflammation, metaflammation, dysbiosis, Intestinal permeability, chronic stress, or persistent viral infections. The patient presents with Metabolic Depression -- profound fatigue, hypersomnia, cognitive fog, weight gain, low body temperature -- yet standard blood work appears normal. Treating this condition requires addressing the inflammatory root cause rather than simply supplementing thyroid hormone, although judicious use of T3 can sometimes break the cycle.
Autoimmune thyroid disease represents the quintessential cPNI case study, illustrating the convergence of genetic susceptibility (HLA antigens), environmental triggers (molecular mimicry, Iodine excess, Selenium deficiency, Vitamin D deficiency, dysbiosis), barrier dysfunction (Intestinal permeability), and psychoneuroimmune dysregulation (chronic stress, loss of vagal tone). Hashimoto's thyroiditis -- the most common autoimmune disease worldwide -- is driven by Th1-mediated destruction of thyroid follicular cells and production of anti-TPO and anti-thyroglobulin antibodies. Graves' disease, by contrast, involves stimulatory antibodies against the TSH receptor that cause uncontrolled thyroid hormone production, weight loss, tachycardia, anxiety, and ophthalmopathy. Both conditions share common upstream drivers: all five cPNI metamodels are implicated. The gut-thyroid connection is particularly strong, with up to 50% of Hashimoto's patients showing concurrent Coeliac disease or Gluten sensitivity, and dysbiosis driving molecular mimicry between bacterial antigens and thyroid tissue. Selenium supplementation (200 micrograms daily) has been shown to reduce anti-TPO antibodies by 30-50%, demonstrating that even a single micronutrient intervention targeting the HPT axis can modulate autoimmune pathology.